Properties (63)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
biotechnology company
|
| gptkbp:acquisition |
Acquired by a larger pharmaceutical company
|
| gptkbp:businessModel |
biopharmaceutical development
focus on strategic partnerships |
| gptkbp:CEO |
Michael_Gold
|
| gptkbp:clinicalTrials |
Phase 3 trials
Phase 1, Phase 2, Phase 3 published in peer-reviewed journals conducts clinical trials positive outcomes reported aims to improve patient care monitors and evaluates results recruits patients for studies OTX-DS_for_dry_eye_disease OTX-TP_for_glaucoma various_sites_across_the_US |
| gptkbp:collaborations |
with academic institutions
|
| gptkbp:community |
aims to improve eye health
|
| gptkbp:communityEngagement |
participates in health initiatives
|
| gptkbp:employees |
approximately 100
|
| gptkbp:financialPerformance |
reported revenue growth
|
| gptkbp:financials |
receives from investors
|
| gptkbp:focus |
ophthalmic therapeutics
|
| gptkbp:focusArea |
sustained-release therapies
|
| gptkbp:founded |
2014
|
| gptkbp:futurePlans |
expand into international markets
|
| gptkbp:hasCompetitors |
other biotech firms
|
| gptkbp:headquarters |
gptkb:Bedford,_Massachusetts
|
| gptkbp:historicalResearch |
conducts studies on eye diseases
|
| https://www.w3.org/2000/01/rdf-schema#label |
Ocular Therapeutix, Inc.
|
| gptkbp:innovation |
drug delivery technology
|
| gptkbp:investmentFocus |
Venture capital firms
raised over $100 million maintains communication with investors |
| gptkbp:leads |
various venture capitalists
|
| gptkbp:market |
approximately $200 million
Dextenza in 2019 growing in the ophthalmic sector |
| gptkbp:marketingStrategy |
focus on innovation
|
| gptkbp:marketSegment |
targeting ophthalmic markets
|
| gptkbp:partnerships |
with healthcare providers
Allergan |
| gptkbp:patentCitation |
multiple patents granted
|
| gptkbp:patentType |
Dextenza in 2018
|
| gptkbp:productLine |
includes multiple candidates
|
| gptkbp:products |
gptkb:Ocular_Therapeutix_OTX-TP
ongoing for new therapies Dextenza Ocular Therapeutix Dextenza |
| gptkbp:regulatoryCompliance |
publicly traded company
follows_FDA_regulations |
| gptkbp:research |
secured funding for R&D
|
| gptkbp:research_areas |
eye diseases
|
| gptkbp:researchFocus |
sustained-release drug delivery systems
|
| gptkbp:researchInterest |
with universities and research institutions
|
| gptkbp:scientificName |
renowned experts in ophthalmology
|
| gptkbp:stockSymbol |
OCUL
|
| gptkbp:strategicGoals |
expand product pipeline
|
| gptkbp:supplyChain |
collaborates with manufacturers
|
| gptkbp:targetMarket |
ophthalmology
|
| gptkbp:technology |
sustained-release technology
|
| gptkbp:tradedOn |
gptkb:NASDAQ
|
| gptkbp:website |
www.oculartx.com
|